MedTrace Logo

SENOC-I Det Sunda Huset II - Sensitization of Occupants of Water Damaged Buildings.

NCT00143650 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2007-01-17

No results posted yet for this study

Summary

The study is focussed on two main questions:

1. The importance of dampness of the building and home dust as a factor of the subjects= responses.
2. Can measures used in KLINIR predict the subjects' responses to the dust?

This study therefore was arranged to test the following hypotheses:

1. Does dust in general cause inflammatory/body perceptions through e.g. an irritation symptoms index.
2. Does the dust include effective odorants which affects an IAQ index?
3. Does dampness increase the content of organic or inorganic compounds e.g. of microbial origin that causes the dust to be more reactive? (Differences between the two types of dust)
4. Is the sensitivity of the subjects explaining the responses to exposures in a, b, or c? (Subject group and sensitivity index)

As explorative investigations biomarkers for exposures and sensitivity for practical usage are tested.

Conditions

  • Upper Airway, Irritation Inflammation, Discomfort

Interventions

BEHAVIORAL

House dust

Sponsors & Collaborators

  • The Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning (FORMAS)

    collaborator OTHER_GOV

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Lars Mølhave,, DMSc, Ph.D. · The Air Pollution Unit, Department of Environmental and Occupational Medicine, Institute of Public Health, The University of Aarhus

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-01-31
Completion
2002-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00143650 on ClinicalTrials.gov